Sergio Sismondo is Professor of Philosophy and Sociology at Queen’s University, Canada. His current work, including a number of recent articles, explores the pharmaceutical industry’s development and deployment of clinical research, focusing on intersections of marketing and science. He is the author and co-author of a number of books, including An Introduction to Science and Technology Studies, Second Edition (Wiley Blackwell, 2010) and The Art of Science (2003). He is Editor of the journal Social Studies of Science.Jeremy A. Greene is Elizabeth Treide and A. McGehee Harvey Chair in the History of Medicine at Johns Hopkins University. His recent work focuses on the ways in which the development and consumption of therapeutics interact with our understandings of what it means to be sick or healthy, normal or abnormal. His broader research interests focus on the history of disease, the history of global health, and the history of the pharmaceutical industry and its interactions with medical research, clinical practice, and public health.  He is the author of Generic: The Unbranding of Modern Medicines (2014) and Prescribing by Numbers: Drugs and the Definition of Disease (2007), as well as co-editor of Prescribed: Writing, Filling, Using, and Abusing the Prescription in Modern America (2012).

"...provides an in-depth look at the machinery that enables the continued expansion of pharmaceutical products, markets, and subjects." - Ellen Rubinstein for Anthropology Book Forum, Anthropology News

• Acknowledgements vii1 Introduction 1Jeremy A. Greene and Sergio SismondoPart I Pharmaceutical Lives 172 The Pharmaceuticalisation of Society? A Framework for Analysis 19Simon J. Williams, Paul Martin and Jonathan Gabe3 Pharmaceutical Witnessing: Drugs for Life in an Era of Direct]to]Consumer Advertising 33Joseph DumitPart II New Drugs, Diseases, and Identities 494 Releasing the Flood Waters: Diuril and the Reshaping of Hypertension 51Jeremy A. Greene5 DepRession and ConsumŠtion: Psychopharmaceuticals, Branding, and New Identity Practices 70Nathan Greenslit6 BiDil: Medicating the Intersection of Race and Heart Failure 87Anne Pollock7 Manufacturing Desire: The Commodification of Female Sexual Dysfunction 106Jennifer R. FishmanPart III Drugs and the Circulation of Medical Knowledge 1218 Following the Script: How Drug Reps Make Friends and Influence Doctors 123Adriane Fugh]Berman and Shahram Ahari9 Getting to Yes: Corporate Power and the Creation of a Psychopharmaceutical Blockbuster 133Kalman Applbaum10 Pushing Knowledge in the Drug Industry: Ghost]Managed Science 150Sergio Sismondo11 Transcultural Medicine: A Multi]Sited Ethnography on the Scientific]Industrial Networking of Korean Medicine 165Jongyoung KimPart IV Political and Moral Economies of Pharmaceutical Research 17912 Uncommon Trajectories: Steroid Hormones, Mexican Peasants, and the Search for a Wild Yam 181Gabriela Soto Laveaga13 “Ready]to]Recruit” or “Ready]to]Consent” Populations? Informed Consent and the Limits of Subject Autonomy 195Jill A. Fisher14 Clinical Trials Offshored: On Private Sector Science and Public Health 208Adriana Petryna15 The Experimental Machinery of Global Clinical Trials: Case Studies from India 222Kaushik Sunder RajanPart V Intellectual Property in Local and Global Markets 23516 Intellectual Property and Public Health: Copying of HIV/AIDS Drugs by Brazilian Public and Private Pharmaceutical Laboratories 237Maurice Cassier and Marilena Correa17 Global Pharmaceutical Markets and Corporate Citizenship: The Case of Novartis’ Anti]Cancer Drug Glivec 247Stefan Ecks18 Generic Medicines and the Question of the Similar 261Cori HaydenIndex 268